107 related articles for article (PubMed ID: 26543076)
1. Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma.
Lai X; Chen S
Cancer Genomics Proteomics; 2015; 12(6):271-81. PubMed ID: 26543076
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.
Lai X; Umbricht CB; Fisher K; Bishop J; Shi Q; Chen S
J Proteomics; 2017 Aug; 166():59-67. PubMed ID: 28709933
[TBL] [Abstract][Full Text] [Related]
3. Proteomics for the diagnosis of thyroid lesions: preliminary report.
Pagni F; Mainini V; Garancini M; Bono F; Vanzati A; Giardini V; Scardilli M; Goffredo P; Smith AJ; Galli M; De Sio G; Magni F
Cytopathology; 2015 Oct; 26(5):318-24. PubMed ID: 25040579
[TBL] [Abstract][Full Text] [Related]
4. Classification of Thyroid Tumors Based on Mass Spectrometry Imaging of Tissue Microarrays; a Single-Pixel Approach.
Kurczyk A; Gawin M; Chekan M; Wilk A; Łakomiec K; Mrukwa G; Frątczak K; Polanska J; Fujarewicz K; Pietrowska M; Widlak P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878024
[TBL] [Abstract][Full Text] [Related]
5. The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours.
Mato E; Barceló-Batllori S; Orera I; Selva L; Corra M; González C; Bell O; Lerma E; Moral A; Pérez JI; de Leiva A
Mol Cell Endocrinol; 2015 Mar; 404():37-45. PubMed ID: 25617717
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
7. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors.
Jacques C; Guillotin D; Fontaine JF; Franc B; Mirebeau-Prunier D; Fleury A; Malthiery Y; Savagner F
J Clin Endocrinol Metab; 2013 May; 98(5):E981-9. PubMed ID: 23569218
[TBL] [Abstract][Full Text] [Related]
8. Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
Nelson KK; Gattuso P; Xu X; Prinz RA
Surgery; 2010 Oct; 148(4):654-60; discussion 660. PubMed ID: 20797751
[TBL] [Abstract][Full Text] [Related]
9. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma.
Lai X; Chen S
Proteomics; 2015 Jul; 15(13):2358-68. PubMed ID: 25755173
[TBL] [Abstract][Full Text] [Related]
11. [Proteomics study of papillary thyroid carcinoma].
Shi J; Lu ZH; Cui QC
Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):465-70. PubMed ID: 19035118
[TBL] [Abstract][Full Text] [Related]
12. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors.
West J; Munoz-Antonia T; Johnson JG; Klotch D; Muro-Cacho CA
Laryngoscope; 2000 Aug; 110(8):1323-7. PubMed ID: 10942134
[TBL] [Abstract][Full Text] [Related]
14. Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas.
Yu SY; Hong LC; Feng J; Wu YT; Zhang YZ
Tumour Biol; 2016 Jul; 37(7):8923-30. PubMed ID: 26753958
[TBL] [Abstract][Full Text] [Related]
15. Analysis of lectin binding in benign and malignant thyroid nodules.
Sasano H; Rojas M; Silverberg SG
Arch Pathol Lab Med; 1989 Feb; 113(2):186-9. PubMed ID: 2916907
[TBL] [Abstract][Full Text] [Related]
16. Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis.
Uzozie AC; Selevsek N; Wahlander A; Nanni P; Grossmann J; Weber A; Buffoli F; Marra G
Mol Cell Proteomics; 2017 Mar; 16(3):407-427. PubMed ID: 28062797
[TBL] [Abstract][Full Text] [Related]
17. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
18. Delta Np73 expression in thyroid neoplasms originating from follicular cells.
Ito Y; Uramoto H; Funa K; Yoshida H; Jikuzono T; Asahi S; Higashiyama T; Tomoda C; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Miyauchi A
Pathology; 2006 Jun; 38(3):205-9. PubMed ID: 16753740
[TBL] [Abstract][Full Text] [Related]
19. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome.
Heikkilä A; Hagström J; Mäenpää H; Louhimo J; Siironen P; Heiskanen I; Haglund C; Arola J
Thyroid; 2013 Apr; 23(4):456-65. PubMed ID: 23106428
[TBL] [Abstract][Full Text] [Related]
20. Bauhinia purpurea (BPA) binding to normal and neoplastic thyroid glands.
Sarker AB; Akagi T; Teramoto N; Nose S; Yoshino T; Kondo E
Pathol Res Pract; 1994 Nov; 190(11):1005-11. PubMed ID: 7746733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
